Takeda Pharmaceuticals Ltd. continued its recent love affair with U.S. biologics, entering into an agreement to purchase Millennium Pharmaceuticals Inc. for $8.8 billion, and instantly gaining a strong foothold in the cancer field. (BioWorld Today)